Hideki Garren
Genentech · 83 works · 10,152 citations · h-index 33
Top works
- Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- The drosophila sine oculis locus encodes a homeodomain-containing protein required for the development of the entire visual system
- Suppressive Immunization with DNA Encoding a Self-Peptide Prevents Autoimmune Disease: Modulation of T Cell Costimulation
- The Drosophila anachronism locus: A glycoprotein secreted by glia inhibits neuroblast proliferation
- Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite
- Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
- Antibody labeling of functional subdivisions in visual cortex: Cat-301 immunoreactivity in striate and extrastriate cortex of the macaque monkey
- Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis
- Combination of Gene Delivery and DNA Vaccination to Protect from and Reverse Th1 Autoimmune Disease via Deviation to the Th2 Pathway
- Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington’s disease brain nuclei
- Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8 + T Cells in Type 1 Diabetes
- Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study
- Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis
- Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination
- Induction of Antigen-Specific Tolerance in Multiple Sclerosis After Immunization With DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controlled Phase 1/2 Trial
- An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems
- Microbial Epitopes Act as Altered Peptide Ligands to Prevent Experimental Autoimmune Encephalomyelitis
- The specificity of the antibody response in multiple sclerosis